Featured Trials

  • Is your acne holding you back?

    The Face It Acne Research Studies measure and evaluate the effectiveness of the reduction of inflammatory facial acne lesions through the means of a topical solution and pulsed laser. Males and females, ages 12 or older, with moderate to severe facial acne, will participate in the studies.

  • Research study for Advanced Hereditary Breast Cancer

    The Brocade3 study is a research study evaluating the safety and effectiveness of an investigational, oral medication in addition to treatment with chemotherapy for patients with metastatic or locally advanced BRCA-associated breast cancer.

  • Losing your Hair? Unhappy with your Bald spot?

    The Vertex Hair Growth Research Study is evaluating the safety and effectiveness of an investigational oral drug for Androgenetic Alopecia (AGA), also known as male pattern baldness. This research study is currently enrolling men ages 18 – 41 years old with mild to moderate male pattern baldness.

Enrollment Support

Do you need to enroll more patients?

MyClinicalTrial.com is an exclusive service provided by Clinical Site Services (CSS). CSS has planned and placed media for select client sites across the country, delivering in many cases a 30-100% increase in recruitment response. CSS provides:

  • Development of recruitment tools and materials
  • Effective planning and placement of media (including print, television, radio, direct mail, and internet) within the sponsor allocated budget
  • Pre-screening 100% of subject calls for sites – through our 24-hour integrated voice and web system
  • IRB submission of recruitment tools and materials
  • Recruitment budget requests and negotiation with study sponsor(s)
  • ALL SERVICES PROVIDED AT NO COST TO THE SITE

For additional information, please visit www.cssienroll.com.

Trial Locator Services

Are you looking for more studies?

Most study sites have the capabilities to perform additional studies but do not have resources or expertise to locate new studies. Our sister company, Site Management Solutions (SMS), has established relationships with pharmaceutical companies and CROs and is aware of currently recruiting studies in the planning stages. While there are other companies offering similar services, investigative sites prefer SMS because of the following:

  1. Non-exclusive agreements
  2. Flat fee based pricing and not per patient financial commitments
  3. Discounts for working with our partner companies

To find out more, please visit www.SMSclinical.com.